Introduction {#s1}
============

Cardiovascular disease is one of the leading causes of premature death \[[@R01]\]. High blood pressure (BP) is one of the most important modifiable risk factors of cardiovascular disease and approximately a half of fatal cardiovascular events are estimated to be attributable to hypertension \[[@R02]\]. In Japan, average BP levels have declined during the past few decades (probably due to improvement in treatment and control of hypertension), while prevalence rates of hypertension have remained stable \[[@R03]\]. Effective prevention of hypertension and subsequent cardiovascular events will require strategies based on up-to-date knowledge on risk factors of hypertension.

A number of observational studies reported the association between serum uric acid and hypertension in a variety of populations, while no clear associations were reported from other observational or Mendelian randomization studies \[[@R04], [@R05]\]. As a result, uncertainty remains surrounding the causal relationship between serum uric acid and hypertension. The aim of this study was to investigate the association between serum uric acid and prevalence of hypertension in a general population of Japanese.

Materials and Methods {#s2}
=====================

Study design and participants {#s2a}
-----------------------------

The Iki Epidemiological Study of Atherosclerosis and Chronic Kidney Disease (ISSA-CKD) is a population-based observational study of the residents of the Iki City, Nagasaki Prefecture, Japan. Details of the ISSA-CKD study have been described previously \[[@R06], [@R07]\]. In brief, a total of 7,895 residents aged 30 years or older underwent annual health check-ups conducted by the local government of the Iki City between 2008 and 2017. After exclusion of 411 residents with missing information on age, sex, serum uric acid, BP or use of BP lowering medication, a total of 7,484 participants were included in the present analysis. This study was conducted in compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects of Japan as well as with the Helsinki Declaration, and was approved by the Fukuoka University Clinical Research & Ethics Centre (No. 2017M010).

Data collection {#s2b}
---------------

Information on smoking habits and alcohol intake was obtained using a standard questionnaire. Current smoking was defined as participants who had smoked 100 cigarettes or more, or who had smoked regularly for more than 6 months. Alcohol intake was classified into current daily drinking or not. Height and weight were measured with the participant wearing light clothes without shoes, and body mass index (BMI, kg/m^2^) was calculated. Obesity was defined as BMI ≥ 25 kg/m^2^. BP was measured by trained staff in the right upper arm using mercury, automated, or aneroid sphygmomanometers with appropriately sized cuffs, after at least 5 min of rest in a sitting position, in accordance with standardized guidelines \[[@R08]\]. BP was measured twice and the mean of the two values was used in the present analysis. Casual blood and urine samples were collected. Serum uric acid was determined using the enzyme method and classified into four groups: group 1 (\< 357 µmol/L (\< 6 mg/dL)), group 2 (357 - 415 µmol/L (6 - 6.9 mg/dL)), group 3 (416 - 475 µmol/L (7 - 7.9 mg/dL)) and group 4 (≥ 476 µmol/L (≥ 8 mg/dL)). Plasma glucose concentration was determined using the enzyme method and glycated hemoglobin (HbA1c) level (NGSP value) was determined using the high-performance liquid chromatography method. Presence of diabetes was defined as fasting glucose concentration ≥ 7.0 mmol/L, non-fasting glucose concentration ≥ 11.1 mmol/L, HbA1c ≥ 6.5%, or use of glucose lowering therapy. Serum low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels were determined enzymatically. Dyslipidemia was defined by LDL cholesterol ≥ 3.62 mmol/L, HDL cholesterol \< 1.03 mmol/L, triglycerides ≥ 1.69 mmol/L, or use of lipid lowering medications. Serum creatinine concentration was determined using an enzymatic method and estimated glomerular filtration rate (eGFR) was estimated using the formula of the Japanese Society of Nephrology, as follows: eGFR (mL/min/1.73 m^2^) = 194 × serum creatinine (mg/dL)^-1.094^ × age^-0.287^ (× 0.739 if female) \[[@R9]\]. Urinary protein concentration was evaluated using dipsticks, and (1+) or higher score was regarded as the presence of proteinuria. Chronic kidney disease (CKD) was defined as eGFR \< 60 mL/min/1.73 m^2^ and/or presence of proteinuria.

Definition of hypertension {#s2c}
--------------------------

Hypertension was defined as BP levels of ≥ 140/90 mm Hg or use of BP lowering medications.

Statistical analysis {#s2d}
--------------------

Continuous variables were expressed as mean (standard deviation (SD)) and compared using analysis of variance. Categorial variables were expressed as number of participants (percentage) and compared using Chi-squared tests. Crude and multivariable-adjusted odds ratios (ORs) and their 95% confidence intervals (95% CIs) were estimated using logistic regression models. A two-tailed P value of less than 0.05 was considered statistically significant. Analyses were carried out using the SAS version 9.4.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} shows the characteristics according to groups defined by serum uric acid levels. Participants with higher serum uric acid levels were more likely to be male, current smokers, current drinkers and obese, and were more likely to have dyslipidemia and CKD.

###### Baseline Characteristics According to Serum Uric Acid Levels

                                                           Uric acid      P value                                      
  -------------------------------------------------------- -------------- -------------- -------------- -------------- ----------
  Age, years                                               59.3 (11.8)    59.5 (11.5)    58.6 (12.0)    57.8 (12.0)    0.104
  Male                                                     1,826 (33%)    950 (80%)      488 (90%)      227 (90%)      \< 0.001
  Current smoking                                          924 (17%)      347 (29%)      178 (33%)      82 (33%)       \< 0.001
  Current alcohol intake                                   855 (17%)      441 (41%)      235 (49%)      111 (51%)      \< 0.001
  Body mass index, kg/m^2^                                 23.3 (3.5)     24.5 (3.4)     25.3 (3.6)     25.6 (3.8)     \< 0.001
  Obesity                                                  1,592 (29%)    476 (40%)      272 (50%)      140 (56%)      \< 0.001
  Systolic blood pressure, mm Hg                           128.2 (19.1)   132.2 (18.5)   132.6 (18.4)   132.6 (17.3)   \< 0.001
  Diastolic blood pressure, mm Hg                          74.0 (11.1)    76.7 (11.3)    78.1 (11.6)    78.7 (12.0)    \< 0.001
  Blood pressure lowering medication                       1,519 (28%)    433 (37%)      201 (37%)      102 (41%)      \< 0.001
  Glycated hemoglobin, %                                   5.3 (0.8)      5.2 (0.6)      5.3 (0.8)      5.3 (0.7)      0.007
  Glucose lowering therapy                                 322 (6%)       78 (7%)        44 (8%)        10 (4%)        0.069
  Diabetes                                                 586 (11%)      133 (11%)      73 (14%)       28 (11%)       0.222
  High-density lipoprotein cholesterol, mmol/L             3.14 (0.82)    3.12 (0.85)    3.09 (0.83)    3.14 (0.98)    0.766
  Low-density lipoprotein cholesterol, mmol/L              1.65 (0.48)    1.50 (0.42)    1.49 (0.48)    1.40 (0.50)    \< 0.001
  Triglyceride, mmol/L                                     1.23 (0.79)    1.56 (1.06)    1.69 (1.18)    2.22 (1.66)    \< 0.001
  Lipid lowering medication                                745 (14%)      150 (13%)      60 (11%)       22 (9%)        0.073
  Dyslipidemia                                             2,115 (38%)    586 (50%)      287 (53%)      176 (70%)      \< 0.001
  Estimated glomerular filtration rate, mL/min/1.73 m^2^   76.5 (15.6)    72.4 (16.3)    68.1 (17)      65.5 (17.4)    \< 0.001
  Proteinuria                                              253 (5%)       85 (7%)        66 (12%)       43 (17%)       \< 0.001
  Chronic kidney disease                                   792 (14%)      266 (23%)      184 (34%)      105 (42%)      \< 0.001

Values are mean (standard deviation), or number of participants (percent).

Hypertension was observed among 3,467 participants (prevalence 46.3%). The prevalence of hypertension increased with elevation of serum uric acid levels: 42.8% in group 1, 55.0% in group 2, 57.6% in group 3 and 59.8% in group 4 (P \< 0.001 for trend) ([Table 2](#T2){ref-type="table"}). This association was significant even after adjustment for other risk factors including age, sex, current smoking, current alcohol intake, obesity, diabetes, dyslipidemia, eGFR and proteinuria: ORs (95% CI) were 1.50 (1.28 - 1.77) for group 2, 1.58 (1.25 - 1.99) for group 3 and 1.89 (1.36 - 2.64) for group 4 compared with the reference group of group 1 (P \< 0 .001 for trend) ([Table 2](#T2){ref-type="table"}). Multivariable-adjusted OR (95% CI) per 1 SD (93 µmol/L (1.57 mg/dL)) increase in serum uric acid was 1.32 (1.22 - 1.43) (P \< 0.001). There were comparable ORs for prevalent hypertension per 1 SD increase of serum uric acid between subgroups defined by gender (OR 1.26 (95% CI 1.14 - 1.40) for male and 1.39 (1.23 - 1.58) for female, P = 0.235 for interaction), current alcohol intake (OR 1.39 (95% CI 1.26 - 1.53) for no current alcohol intake and 1.19 (1.03 - 1.37) for current alcohol intake, P = 0.125 for interaction) or presence of CKD (OR 1.32 (95% CI 1.21 - 1.43) for no CKD and 1.16 (1.01 - 1.33) for CKD, P = 0.847 for interaction) ([Table 3](#T3){ref-type="table"}).

###### Association of Serum Uric Acid and Prevalence of Hypertension

                                      Uric acid     P value for trend                                               
  ----------------------------------- ------------- -------------------- --------------------- -------------------- ----------
  No. of hypertensives/participants   2,356/5,510   650/1,183            311/540               150/251              
  Prevalence (%)                      42.8%         55.0%                57.6%                 59.8%                
  Crude OR (95% CI)                   Reference     1.63 (1.44 - 1.85)   1.82 (1.52 -- 2.17)   1.99 (1.54 - 2.57)   \< 0.001
  Adjusted OR^a^ (95% CI)             Reference     1.50 (1.28 - 1.77)   1.58 (1.25 - 1.99)    1.89 (1.36 - 2.64)   \< 0.001

^a^Adjusted for age, sex, current smoking, current alcohol intake, obesity, diabetes, dyslipidemia, estimated glomerular filtration rate and proteinuria. OR: odds ratio; CI: confidence interval.

###### Association of Serum Uric Acid and Prevalence of Hypertension in Subgroups

  Subgroup                 Adjusted odds ratio per 1 SD^a^ increase in serum uric acid (95% CI)   P value for interaction
  ------------------------ ---------------------------------------------------------------------- -------------------------
  Gender                                                                                          
    Male                   1.26 (1.14 - 1.40)^b^                                                  0.235
    Female                 1.39 (1.23 - 1.58)^b^                                                  
  Current alcohol intake                                                                          
    No                     1.39 (1.26 - 1.53)^c^                                                  0.125
    Yes                    1.19 (1.03 - 1.37)^c^                                                  
  Chronic kidney disease                                                                          
    Absent                 1.32 (1.21 - 1.43)^d^                                                  0.847
    Present                1.16 (1.01 - 1.33)^d^                                                  

^a^93 µmol/L (1.57 mg/dL). ^b^Adjusted for age, current smoking, current alcohol intake, obesity, diabetes, dyslipidemia, estimated glomerular filtration rate and proteinuria. ^c^Adjusted for age, sex, current smoking, obesity, diabetes, dyslipidemia, estimated glomerular filtration rate and proteinuria. ^d^Adjusted for age, sex, current smoking, current alcohol intake, obesity, diabetes and dyslipidemia. SD: standard deviation; CI: confidence interval.

Discussion {#s4}
==========

There was a positive association between serum uric acid and prevalence of hypertension in the present large-scale cross-sectional study of general Japanese. These associations remained significant after adjustment for the effects of confounding factors such as age, sex, current smoking, current alcohol intake, obesity, diabetes, dyslipidemia, eGFR and proteinuria. Comparable associations between serum uric acid and prevalence of hypertension were also observed between subgroups defined by gender, daily alcohol intake and presence of CKD.

Many observational studies reported the association between serum uric acid and hypertension \[[@R10]-[@R14]\]. However, current evidence is mainly derived from Western populations. In contrast, a few epidemiological studies reported the association between hyperuricemia and hypertension among Japanese. The Osaka Health Study reported increased risks of incident hypertension associated with elevation of serum uric acid levels among 6,356 Japanese men aged 35 - 60 years \[[@R15]\]. Nakanishi et al also reported similar associations between serum uric acid levels and incidence of hypertension among 2,310 Japanese male office workers aged 35 - 59 years \[[@R16]\]. Nagahama et al reported 1.57-fold higher risks of incident hypertension in participants with hyperuricemia (416 µmol/L (7 mg/dL) in men or ≥ 357 µmol/L (6 mg/dL) in women) among 4,489 Japanese men and women \[[@R17]\]. The present study of 7,484 general Japanese confirmed the findings from the previous studies and demonstrated that there was a linear association between serum uric acid and prevalence of hypertension from serum uric acid level of ≥ 357 µmol/L (6 mg/dL) in a general population of Japanese.

Emerging evidence suggests a pathogenic role of hyperuricemia in development of CKD \[[@R18]\]. Because CKD is a strong determinant of hypertension, the link between serum uric acid and hypertension might in part be mediated by CKD. However, most prior studies \[[@R10], [@R12]-[@R17]\] (including studies conducted in Japan \[[@R15]-[@R17]\]) did not control for the effects for eGFR or proteinuria in multivariable analyses. In this context, the Framingham study demonstrated significant effects of hyperuricemia on incidence of hypertension, independent of eGFR and proteinuria \[[@R11]\]. The present analysis confirmed the findings of the Framingham study and clearly demonstrated the association between serum uric acid and hypertension independent of eGFR and proteinuria. There were also no clear differences in associations between serum uric acid and prevalence of hypertension irrespective of presence of CKD. Based on the findings above, there seems to be limited role of CKD as a mediator of the link between hyperuricemia and hypertension.

The potential mechanisms underlying the relationship between serum uric and hypertension involve reduction of endothelial nitric oxide, activation of renin-angiotensin system (RAS) \[[@R19], [@R20]\], and renal microvascular diseases due to smooth muscle cell proliferation, inflammation and activation of local RAS \[[@R21]\].

Although this was a large-scale study of a general Japanese population, it has several limitations. First, because of the nature of a cross-sectional design, causal relationship was not clearly defined. Second, findings of this study may be affected by selection bias because participants who attended the health check-ups were more likely to be aware of healthy behaviors. Third, information on use of drugs for hyperuricemia and that on use of different types of BP lowering medications was not available in this study.

Conclusions {#s4a}
-----------

Serum uric acid was clearly associated with prevalence of hypertension in a general population of Japanese.
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